Eucalyptol — 1,8-Cineole (Monoterpene Ether · Mucolytic · Respiratory · Oral Health)

Compound	Eucalyptol (1,8-Cineole)
Chemical class	Terpenoid — Monoterpene Ether (Bicyclic)
CAS	470-82-6
Primary source	Eucalyptus globulus (blue gum), Rosmarinus officinalis (rosemary)
Key applications	Mucolytic, respiratory decongestant, oral antiseptic, cognitive support
Claim strength	Moderate
Typical form	Eucalyptol 80% (1,8-Cineole); eucalyptus extract
Buy from Herbuno

Name origin: From Eucalyptus; systematic name 1,8-Cineole describes the oxygen bridge between positions 1 and 8 of the bicyclic ring. Traditional use: Eucalyptus preparations have been used in Australian Aboriginal medicine and adopted into 19th-century European and American phytomedicine for respiratory complaints, wound antisepsis, and fever management. Rosemary (also high in 1,8-cineole) has traditional Mediterranean use for cognitive support and circulation. Research trajectory: Well-established pharmacological profile for mucolytic, bronchodilatory, anti-inflammatory, and antimicrobial activity, with growing evidence for cognitive function via AChE inhibition. Approved OTC drug active in multiple markets for respiratory applications. Commercial source: Eucalyptol 80% from Eucalyptus globulus and Eucalyptus Extract Powder from Herbuno. See sourcing options below.

---

Evidence for Eucalyptol Applications

Respiratory — mucolytic and COPD: Human RCTs including the EukaXin trial (n=242 COPD patients, 200 mg 3×/day) demonstrate significant reduction in exacerbation frequency with oral 1,8-Cineole versus placebo. Reduces mucus viscosity and improves bronchial clearance. Approved mucolytic in European markets. Claim strength: Moderate.

Oral antiseptic (OTC): FDA-approved OTC oral antiseptic active in Listerine (0.092%) alongside thymol, methyl salicylate, and menthol. RCT evidence for plaque reduction and gingival health. Inhibits COX-2 and NF-κB beyond direct antimicrobial effects. Claim strength: Moderate (OTC approval + RCT).

Cognitive function (AChE inhibition): Inhibits acetylcholinesterase in vitro with potency comparable to some pharmaceutical AChE inhibitors. Human inhalation studies with rosemary oil (eucalyptol-dominant) show improved attention and memory speed task performance. Supports traditional use of rosemary for memory. Claim strength: Moderate.

---

Dosage & Formulator Specification

Respiratory oral (enteric-coated): 200–600 mg/day eucalyptol (EukaXin used 200 mg 3×/day). Enteric coating prevents upper GI irritation; same rationale as peppermint oil IBS capsules. Oral antiseptic mouthwash: 0.092% (FDA monograph). Aromatherapy: 2–5% eucalyptol in carrier for diffusion or steam inhalation. Topical chest rub: up to 5% in cream base. Contraindicated for direct application to face or nostrils of children under 2 years (reflex bronchospasm risk). Eucalyptol 80% is commercially available from eucalyptus extraction — for pharmaceutical applications verify 1,8-Cineole content by GC.

---

Frequently Asked Questions — Eucalyptol

Is eucalyptol the same as eucalyptus oil?
Eucalyptol (1,8-Cineole) constitutes 60–85% of eucalyptus essential oil from Eucalyptus globulus. Isolated eucalyptol at 200–600 mg/day is the specifically studied form in respiratory RCTs. Full eucalyptus oil is typical for aromatherapy and topical applications where the complete monoterpene matrix is preferred.

Can eucalyptol be positioned for COPD management?
The EukaXin trial specifically studied eucalyptol 200 mg 3×/day in COPD patients with significant exacerbation reduction over 6 months. Position as "studied to support healthy bronchial function and mucus clearance." Do not position as a COPD treatment — this requires pharmaceutical regulatory pathways. Enteric-coated soft gelatin is the appropriate format.

Does rosemary oil contain the same eucalyptol as eucalyptus oil?
1,8-Cineole is chemically identical regardless of source. Rosemary oil contains 20–50% 1,8-Cineole depending on chemotype (ct. camphor vs ct. 1,8-Cineole). For cognitive aromatherapy applications, specify rosemary oil standardised to 1,8-Cineole content rather than the camphor-dominant chemotype.

Is there synergy between eucalyptol and menthol for respiratory formulations?
Yes — pharmacologically established. Eucalyptol provides mucolytic activity (increases cilia motility, reduces mucus viscosity); menthol provides TRPM8-mediated sensation of airway openness and mild bronchodilation. Both are in Vicks VapoRub for additive respiratory symptom relief addressing both mechanical (mucus clearance) and sensory (perceived ease of breathing) components.

Related compounds: Camphor, Menthol, Thymol, Carvacrol

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery